A novel approach to inhibit bone resorption: Exosite inhibitors against cathepsin K

British Journal of Pharmacology

Volumn 173, Issue 2, 2016, Pages 396-410

  Panwar, Preety ^a,b,c   Søe, Kent ^c   Guido, Rafael Vc ^d   Bueno, Renata V C ^d   Delaisse, Jean Marie ^c   Brömme, Dieter ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Center for Blood Research   (Canada)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABIETANE DERIVATIVE; BIPHENYL DERIVATIVE; CATHEPSIN K; ODANACATIB; TANSHINONE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG THERAPY; FIBROBLAST; HUMAN; METABOLISM; OSTEOCLAST; OSTEOLYSIS; PROTEIN TERTIARY STRUCTURE;

ANIMALS; BIPHENYL COMPOUNDS; BONE RESORPTION; CATHEPSIN K; CATTLE; DITERPENES, ABIETANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; OSTEOCLASTS; PROTEIN STRUCTURE, TERTIARY;

EID: 84953347897     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13383     Document Type: Article

References (43)

1. Aguda AH, Panwar P, Du X, Nguyen NT, Brayer GD, Bromme D, (2014). Structural basis of collagen fiber degradation by cathepsin K. Proc Natl Acad Sci U S A 111: 17474-17479.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The concise guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
3. Bai X, Jing L, Li Y, Li Y, Luo S, Wang S, et al., (2014). TMEPAI inhibits TGF-beta signaling by promoting lysosome degradation of TGF-beta receptor and contributes to lung cancer development. Cell Signal 26: 2030-2039.
4. Bertazzo S, Gentleman E, Cloyd KL, Chester AH, Yacoub MH, Stevens MM, (2013). Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nat Mater 12: 576-583.
5. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaisse JM, (2005). Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 65: 9943-9952.
6. Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, et al., (2015). Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int 26: 699-712.
7. Bromme D, Lecaille F, (2009). Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 18: 585-600.
8. Buhling F, Rocken C, Brasch F, Hartig R, Yasuda Y, Saftig P, et al., (2004). Pivotal role of cathepsin K in lung fibrosis. Am J Pathol 164: 2203-2216.
9. Chapurlat RD, (2014). Treatment of postmenopausal osteoporosis with odanacatib. Expert Opin Pharmacother 15: 559-564.
10. Chen YG, (2009). Endocytic regulation of TGF-beta signaling. Cell Res 19: 58-70.
11. Cherney MM, Lecaille F, Kienitz M, Nallaseth FS, Li Z, James MN, et al., (2011). Structure-activity analysis of cathepsin K/chondroitin 4-sulfate interactions. J Biol Chem 286: 8988-8998.
12. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP, (2011). Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 7: 447-456.
13. Dauth S, Sirbulescu RF, Jordans S, Rehders M, Avena L, Oswald J, et al., (2011). Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. BMC Neurosci 12: 74.
14. Delaisse JM, (2014). The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation. BoneKEy reports 3: 561.
15. Desmarais S, Black WC, Oballa R, Lamontagne S, Riendeau D, Tawa P, et al., (2008). Effect of cathepsin K inhibitor basicity on in vivo off-target activities. Mol Pharmacol 73: 147-156.
16. Dossetter AG, Beeley H, Bowyer J, Cook CR, Crawford JJ, Finlayson JE, et al., (2012). (1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1, 3, 4, 5-tetrahydropyrido[4, 3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD 4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis. J Med Chem 55: 6363-6374.
17. Du X, Chen NL, Wong A, Craik CS, Bromme D, (2013). Elastin degradation by cathepsin V requires two exosites. J Biol Chem 288: 34871-34881.
18. Feng X, McDonald JM, (2011). Disorders of bone remodeling. Annu Rev Pathol 6: 121-145.
19. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al., (2006). Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177-6196.
20. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al., (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749.
21. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al., (2003). The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18: 859-867.
22. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong le T, Falgueyret JP, et al., (2008). The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18: 923-928.
23. Guo Y, Li Y, Xue L, Severino RP, Gao S, Niu J, et al., (2014). Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. J Ethnopharmacol.
24. Helali AM, Iti FM, Mohamed IN, (2013). Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis. Curr Drug Targets 14: 1591-1600.
25. Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, et al., (2001). Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 159: 2167-2177.
26. Leask A, Abraham DJ, (2004). TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
27. Leung P, Pickarski M, Zhuo Y, Masarachia PJ, Duong LT, (2011). The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 49: 623-635.
28. Li Z, Hou WS, Escalante-Torres CR, Gelb BD, Bromme D, (2002). Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J Biol Chem 277: 28669-28676.
29. Li Z, Kienetz M, Cherney MM, James MN, Bromme D, (2008). The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex. J Mol Biol 383: 78-91.
30. Linnevers CJ, McGrath ME, Armstrong R, Mistry FR, Barnes M, Klaus JL, et al., (1997). Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Sci 6: 919-921.
31. Panwar P, Du X, Sharma V, Lamour G, Castro M, Li H, et al., (2013). Effects of cysteine proteases on the structural and mechanical properties of collagen fibers. J Biol Chem 288: 5940-5950.
32. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
33. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM, (2009). Expression and regulation of cathepsin K in skin fibroblasts. Exp Dermatol 18: 596-602.
34. Rogers MJ, (2003). New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643-2658.
35. Runger TM, Adami S, Benhamou CL, Czerwinski E, Farrerons J, Kendler DL, et al., (2012). Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 66: e89-e96.
36. Sharma V, Panwar P, O'Donoghue AJ, Cui H, Guido RV, Craik CS, et al., (2015). Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor. Biochem J 465: 163-173.
37. Sims NA, Ng KW, (2014). Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep 12: 98-106.
38. Soe K, Delaisse JM, (2010). Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res 25: 2184-2192.
39. Soe K, Merrild DM, Delaisse JM, (2013). Steering the osteoclast through the demineralization-collagenolysis balance. Bone 56: 191-198.
40. Stoch SA, Wagner JA, (2008). Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 83: 172-176.
41. Sun L, Forni S, Schwartz MS, Breidinger S, Woolf EJ, (2012). Quantitative determination of odanacatib in human plasma using liquid-liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis. J Chromatogr B Analyt Technol Biomed Life Sci 885-886: 15-23.
42. Zhang D, Leung N, Weber E, Saftig P, Bromme D, (2011). The effect of cathepsin K deficiency on airway development and TGF-beta1 degradation. Respir Res 12: 72.
43. Zhuo Y, Gauthier JY, Black WC, Percival MD, Duong LT, (2014). Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Bone 67: 269-280.